Tegaserod maleate

TargetMol
Product Code: TAR-T1551
Supplier: TargetMol
CodeSizePrice
TAR-T1551-10mg10mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1551-1mL1 mL * 10 mM (in DMSO)£105.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1551-25mg25mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1551-50mg50mg£168.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1551-100mg100mg£242.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1551-200mg200mg£325.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1551-500mg500mg£500.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke.
CAS:
189188-57-6
Formula:
C20H27N5O5
Molecular Weight:
417.466
Pathway:
GPCR/G Protein; Neuroscience
Purity:
0.9906
SMILES:
OC(=O)C=C/C(O)=O.CCCCCNC(=N)NN=Cc1c[nH]c2ccc(OC)cc12
Target:
5-HT Receptor

References

1. Beattie DT, et al. Br J Pharmacol. 2004 Nov;143(5):549-60. 2. Zhang L, Song Q, Zhang X, et al. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling[J]. Investigational New Drugs. 2019 May 14: 1-10.